Search results
Apr 2, 2024 · SOUTH SAN FRANCISCO, Calif., April 2, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share.
- 3.8900Add to watchlist+0.0600 (+1.57%)At close:4:00 PM EDTMon. May 6, 20243.9700 +0.08 (+2.06%)After hrs:4:20 PM EDTMon. May 6, 2024Nasdaq Real Time Price (USD) · Market closed
- Open3.8900High3.9650Low3.8450
- Mkt Cap318.06MP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close3.830052 Wk. Low2.010052 Wk. High6.1300
Top storiesAnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?Yahoo Finance · 6 days agoRelated stocks
Apr 29, 2024 · STRO Sutro Biopharma, Inc. Stock Price & Overview. Follow. 1.81K followers. $3.42 0.00 ( 0.00%) 4:00 PM 04/26/24. NASDAQ | $USD | Post-Market: $3.51 +0.09 (+2.63%) 7:17 PM. Summary....
Apr 30, 2024 · Apr 4, 2024. read more. Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering. Apr 2, 2024. read more. Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors. Apr 1, 2024. read more.
6 days ago · Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients.
Apr 2, 2024 · Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology,…
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for...
Sutro is the leading water monitoring device for people who want total control over their pool management.